Cervical cancer is an atypical development of cervical cells in the cervix and is generally caused by the human papillomavirus (HPV). The majority of the cancers are caused due to HPV 18 and HPV 16 virus, which are also the causative of penile cancer and anal cancer in men. However, HPV 11 and HPV 6 are normally linked to causing genital warts. Thus, with the rising digit of diagnostic tests such as HPV testing, colposcopy, and Pap smear tests for early recognition, the requirement of such market is expected to be boosted in the near future. As per the report, the worldwide Cervical Cancer Diagnostic Test Market was valued for USD 6.70 Billion in 2015 and is projected to achieve USD 9.46 Billion by 2021, developing at a 5.9% CAGR between 2015 and 2021.
The worldwide market is anticipated to witness a significant growth in the near future owing to the rising number of HPV-infected women around the world. Other factors that are contributing to the growth of the market include several lifestyle-related aspects, such as obesity, smoking, having multiple sex partners, and unsafe sex with inherited HPV-positive patient. Nevertheless, the lack of understanding about the incidence of cervical cancer and the reluctance of the female population to undertake cervical cancer diagnosis are few of the factors that can hamper the market growth.
The major players in the market include Becton, Dickinson and Company, Abbott Laboratories, Hologic, Inc., Femasys, Inc., OncoHealth Corp., Guided Therapeutics, Inc., Roche Diagnostics, Quest Diagnostics, Inc., Silicon Ltd., and QIAGEN.
On the basis of the test, the worldwide market is classified into colposcopy, Pap smear tests, endocervical curettage, HPV testing, and others (loop electrosurgical excision procedure and cone biopsy). On the basis of end-user, the worldwide market is categorized into laboratories, hospitals, and others.
Request for Sample Report @ https://www.zionmarketresearch.com/sample/cervical-cancer-diagnostic-test-market
According to a research article published on ScienceDaily, Sharon Xiaolei Huang and her team from the Lehigh University has developed a technique for screening of cervical cancer. The new screening device is designed based on image-based classifiers that have been created from a huge digit of Cervigram images. The pictures, when read, can assist in identifying the cervical intraepithelial neoplasia.